Drug Profile
GT 4001
Latest Information Update: 08 Aug 1997
Price :
$50
*
At a glance
- Originator Gliatech (CEASED)
- Class Antidementias; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 08 Aug 1997 Discontinued-preclinical in Alzheimer's disease in USA (Unknown route)
- 14 Mar 1995 Preclinical development for Alzheimer's disease in USA (Unknown route)